The aesthetic industry is buzzing due to the recent FDA-approval of Jeuveau! Jeuveau DC is the first new neurotoxin the enter the market in nearly a decade and has been branded as #NEWTOX.
Continue reading to learn all about Jeuveau DC, including how it works, expected results, and its ability to compete with Botox and other antiaging injectables.
What is Jeuveau DC?
Jeuveau is a new FDA-approved neurotoxin treatment designed to smooth moderate to severe lines. It is specifically cleared for the correction of glabellar lines, which are vertical lines that form between the eyebrows with certain facial expressions – like frowning.
How Does Jeuveau Work?
Like Botox, Dysport, and Xeomin, Jeuveau is comprised of botulinum toxin type A. When injected into targeted facial muscles, it interferes with communication between nerves and muscles. This prevents contraction and reduces the muscle’s ability to wrinkle skin.
Jeuveau vs. Botox – What’s the Difference?
When it comes to comparing Jeuveau vs. Botox, there are far more similarities than differences. In fact, Jeuveau is identical to Botox on a molecular level and provides similar efficacy and safety profiles.
As such, Jeuveau DC can be used interchangeably with Botox and offers patients another safe and effective neurotoxin option.
What Areas Can Jeuveau Treat?
While Botox is approved for a number of therapeutic applications, Jeuveau is meant for aesthetic use only. It is currently cleared for treatment of moderate to severe glabellar lines also known as frown lines or “11’s”.
That being said, an experienced injector may choose to use Jeuveau off-label for relaxing other expression lines, including horizontal forehead lines and crow’s feet.
How Long Does Jeuveau DC Last?
Jeuveau results usually last 3-4 months, which is comparable to Botox, Dysport, and Xeomin.
Interested in Trying Jeuveau? Call to Get Started!
If you are considering Jeuveau DC, please contact our office today to schedule a comprehensive consultation with board-certified dermatologists and leading injectors Dr. Dale Isaacson and Dr. Marilyn Berzin.